A Current Overview of Quality-of-Life Research in Chronic Myeloid Leukemia (CML).

Cancers (Basel) · 2026 · PMC13072428 · PMID 41976356

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

HRQoL data from the ASCEMBL trial comparing asciminib to bosutinib in patients with CML-CP previously treated with ≥2 TKIs showed a trend of improvement in the MDASI-CML and EQ-5D-5L scores in the asciminib arm, including fatigue, whereas there was a worsening of gastrointestinal symptoms in the bosutinib arm.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.